Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [31] ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND
    Bozzarelli, S.
    Rimassa, L.
    Giordano, L.
    Garassino, I.
    Marrari, A.
    Tronconi, M. C.
    De Sanctis, R. M.
    Cavina, R.
    Baretti, M.
    Personeni, N.
    Pressiani, T.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 149 - 149
  • [32] An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)
    Dane, F.
    Ozgurdal, K.
    Yalcin, S.
    Benekli, M.
    Aykan, N. F.
    Yucel, I.
    Ozkan, M.
    Evrensel, T.
    Sevinc, A.
    Coskun, H. S.
    Sanli, U. S.
    Kara, I. O.
    ANNALS OF ONCOLOGY, 2015, 26
  • [33] FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
    Calegari, Maria Alessandra
    Zurlo, Ina Valeria
    Di Stefano, Brunella
    Camarda, Floriana
    Di Dio, Carmela
    Garufi, Giovanna
    Cassano, Alessandra
    Barone, Carlo Antonio
    Bria, Emilio
    Basso, Michele
    Orlandi, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [34] A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)
    Suzuki, Takeshi
    Sukawa, Yasutaka
    Imamura, Chiyo K.
    Masuishi, Toshiki
    Satake, Hironaga
    Kumekawa, Yosuke
    Funakoshi, Shinsuke
    Kotaka, Masahito
    Horie, Yoshiki
    Kawai, Sadayuki
    Okuda, Hiroyuki
    Terazawa, Tetsuji
    Kondoh, Chihiro
    Kato, Ken
    Yoshimura, Kenichi
    Ishikawa, Hideki
    Hamarnoto, Yasuo
    Boku, Narikazu
    Takaishi, Hiromasa
    Kanai, Takanori
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 13 - +
  • [35] Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
    Kim, Miso
    Keam, Bhumsuk
    Kim, Tae-Min
    Kim, Hoon-Gu
    Kim, Jin-Soo
    Lee, Sung Sook
    Shin, Seong Hoon
    Kim, Min Kyoung
    Park, Keon Uk
    Kim, Dong-Wan
    Yun, Hwan Jung
    Lee, Jong Seok
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 416 - 422
  • [36] Dose-escalation of REgorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study
    Nishitai, Ryuta
    Manaka, Dai
    Amaike, Hisashi
    Nozaki, Akira
    Kanai, Masashi
    Yamaguchi, Daisuke
    Yazawa, Takeshi
    Kawashima, Kazuhiko
    Ikeda, Fusao
    ANNALS OF ONCOLOGY, 2015, 26 : 129 - 130
  • [37] A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study
    Ross, P. J.
    Repana, D.
    Saunders, M.
    Wilson, R. H.
    Plummer, C. J.
    Summers, J.
    Higgins, F.
    Peacock, J.
    Harari, D.
    Bridgewater, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S69 - S70
  • [38] Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer
    Yoshimatsu, K.
    Yokomizo, H.
    Otani, T.
    Osawa, G.
    Ogawa, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Regorafenib Dose Optimization Study (ReDOS): Randomized Phase II Trial to Evaluate Dosing Strategies for Regorafenib in Refractory Metastatic Colorectal Cancer-An ACCRU Network Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [40] PHASE II STUDY OF OXALIPLATIN AS THIRD-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sikder, S. K.
    Rahman, M.
    Saha, R. K.
    ANNALS OF ONCOLOGY, 2010, 21 : 219 - 219
12345